Biotechnological exploitation of Saccharomyces jurei and its hybrids in craft beer fermentation uncovers new aroma combinations.


Journal

Food microbiology
ISSN: 1095-9998
Titre abrégé: Food Microbiol
Pays: England
ID NLM: 8601127

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 08 01 2021
revised: 16 04 2021
accepted: 25 05 2021
entrez: 21 8 2021
pubmed: 22 8 2021
medline: 11 11 2021
Statut: ppublish

Résumé

Hybridisation is an important evolutionary mechanism to bring about novel phenotypes and may produce new hybrids with advantageous combinations of traits of industrial importance. Within the Saccharomyces genus, Saccharomyces jurei is a newly discovered species and its biotechnological potential has not yet been fully explored. This yeast was found to be able to grow well in unhopped wort and at low temperatures, qualities necessary in good candidates for fermented bevarages. Here, we analysed its fermentation and aroma profile and created novel non-GMO hybrids between S. jurei and S. cerevisiae ale yeasts to develop new starter strains with interesting flavours for the craft brewing and beverage industry in general. Pilot beer fermentations with specific hybrids showed a good fermentation performance, similar to the ale parent strain, while eliminating the hyper-attenuation characteristic and a more complex flavour profile. This study exploits the genetic diversity of yeasts and shows how inter-specific hybridisation and clone selection can be effectively used in brewing to create new products and to eliminate or increase specific traits.

Identifiants

pubmed: 34416971
pii: S0740-0020(21)00103-9
doi: 10.1016/j.fm.2021.103838
pii:
doi:

Substances chimiques

Flavoring Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103838

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Konstantina Giannakou (K)

Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK; Cloudwater Brew Co, 7-8 Piccadilly Trading Estate, Manchester, M1 2NP, UK.

Federico Visinoni (F)

Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

Penghan Zhang (P)

Foundation Edmund Mach, Via Edmund Mach 1, 38010, San Michele all'Adige, TN, Italy.

Nishan Nathoo (N)

Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

Paul Jones (P)

Cloudwater Brew Co, 7-8 Piccadilly Trading Estate, Manchester, M1 2NP, UK.

Mark Cotterrell (M)

Cloudwater Brew Co, 7-8 Piccadilly Trading Estate, Manchester, M1 2NP, UK.

Urska Vrhovsek (U)

Foundation Edmund Mach, Via Edmund Mach 1, 38010, San Michele all'Adige, TN, Italy.

Daniela Delneri (D)

Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK. Electronic address: d.delneri@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH